grade
pharmaceutical primary standard
API family
naloxone
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
SMILES string
N1([C@H]2[C@]3([C@@]4([C@@H](Oc5c4c(ccc5O)C2)C(=O)CC3)CC1)O)CC=C
InChI
1S/C19H21NO4/c1-2-8-20-9-7-18-15-11-3-4-12(21)16(15)24-17(18)13(22)5-6-19(18,23)14(20)10-11/h2-4,14,17,21,23H,1,5-10H2/t14-,17+,18+,19-/m1/s1
InChI key
UZHSEJADLWPNLE-GRGSLBFTSA-N
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Naloxone USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia. Also, for use with USP monographs such as:
- Naloxone Hydrochloride
- Naloxone Hydrochloride Injection
- Pentazocine and Naloxone Tablets
- Buprenorphine and Naloxone Sublingual Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Warning
hcodes
Hazard Classifications
Acute Tox. 4 Oral
保管分類
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Pentazocine and Naloxone Tablets
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 45(1), 3463-3463 (2023)
Naloxone Hydrochloride
United States Pharmacopeia and National Formulary
United States Pharmacopeia, 46(2) (2022)
Daisuke Yamada et al.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 39(8), 1852-1860 (2014-02-13)
Although the underlying mechanism remains unknown, several studies have suggested benefits of n-3 long-chain polyunsaturated fatty acid (PUFA) for patients with anxiety disorders. Elevated fear is thought to contribute to the pathogenesis of particular anxiety disorders. The aim of the